Compare Eli Lilly And Co (LLY) vs United States Natural Gas Fund (UNG) Price & Performance

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

UNG trades at $11.01, down 0.18% on the day, with a bullish technical signal from moving averages and neutral oscillators. The fund reported a net income of $65.15 million for 2024, though revenue was $0, and maintains a strong balance sheet with total assets of $790.02 million and minimal liabilities. Recent news highlights record U.S. natural gas production and geopolitical tensions affecting energy markets.

The outlook for UNG is mixed, with bullish technicals and solid financials offset by exposure to volatile natural gas prices and high production levels. Investment opportunities lie in potential geopolitical supply disruptions, while risks include weather-dependent demand and sustained high output pressuring prices.